Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birtamimab plus standard of care versus placebo plus standard of care in Mayo stage IV AL amyloidosis
MOH_2021-09-19_000670Phase 3Recruiting
- Sponsor
- Prothena Corporation
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Birtamimab + standard of care with Placebo + standard of care (2 arms). Started Aug 2021; status: recruiting.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2021-09-19_000670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-19_000670.